
News followed today that Arista has been awarded a $922,000 U.S. Army contract to be the prime contractor to complete Phase One activities for the development of a new Intelligent Micro-Grid. Upon successful completion of the initial project, the contract has a provision for a Phase II option. Equally important to Arista shareholders, the contract could be a bellwether for future contracts as the U.S. Department of Defense executes initiatives to produce or procure 25% of its total energy from renewable sources by 2025. Shares are climbing on the agreement news; up 9% heading into lunch.
Serving as a solution for military operations that are taking place across a broad spectrum of energy requirements and applications, the Intelligent Micro-Grid will be designed to reliably integrate both renewable and traditional energy sources. Moreover, the Micro-Grid will reduce military dependence on fossil fuels and save lives that can be lost in fuel transportation in military zones.
Arista Power will develop the Intelligent Micro-Grid for the Renewable Energy for Distributed Under-Supplied Command Environments (“REDUCE”) program under the guidance of the U.S. Army Communications-Electronics Research, Development and Engineering Center (“CERDEC”). A demonstration unit is due to CERDEC by Arista within three to six months.
Chief Executive Officer of Arista Power William A. Schmitz commented,
We are pleased to have been selected by the U.S. Army for this vital program and to be playing an integral part in the Department of Defense’s broad-based initiative to reduce its reliance on fossil fuels and to improve energy efficiency. The vast majority of power used by the armed forces for operating environments is provided by diesel generators. Supplying fuel for these generators is costly, not only in a financial sense but also in terms of the dangers to human life inherent in transporting fuel.
Arista Power (ASPWD) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.









According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the
0 comments
Add your comment
Commenting is allowed only for registered users.